Additional coverage pathways Because UHC evaluates each medication under its own clinical policy bulletin, additional FDA-approved indications can open separate coverage pathways sometimes through medical benefit rather than pharmacy benefit
SERS biosensors for ultrasensitive detection of multiple biomarkers expressed in cancer cells
Kryeziu et al., 2013), or proteasome inhibitors (Jung et al., 2012) demonstrate potent profiles on a variety of malignancies, it would be of great interest to investigate the antitumor properties of such inhibitors in combination with the arsenical-based GSH-conjugates GSAO and Darinaparsin
Side effects usually resolve within 4-8 weeks
Arslan, Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity IschemiaReperfusion Injury, MDPI AG, Feb
Chemicals and reagents Cisplatin was obtained from Sigma-Aldrich (St